Ci-Co Healthcare and Piramal Imaging SA, a division of Piramal Enterprises have entered into a strategic partnership and exclusive licensing agreement whereby Ci-Co Healthcare will obtain market authorization from the Korean Health Authorities and commercialize the PET amyloid imaging agent, florbetaben F18, in South Korea. Ci-Co Healthcare has assigned the manufacturing and supply of florbetaben F18 to DuChemBio, a market leading radiopharmacy network in Korea.
Piramal Enterprises is one of India’s largest diversified companies, with a presence in pharmaceutical, financial services and information management sectors.
